Hsbc Holdings PLC Agios Pharmaceuticals, Inc. Transaction History

Hsbc Holdings PLC

$160 Billion
Q2 2024

A detailed history of Hsbc Holdings PLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 5,987 shares of AGIO stock, worth $287,675. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,987

Previous 6,857 12.69%

Holding current value

$287,675

Previous $200,000 29.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$27.55 - $48.83 $23,968 - $42,482	-870 Reduced 12.69%	5,987 $258,000
Q1 2024 May 15, 2024	BUY	$21.32 - $34.81 $146,191 - $238,692	6,857 New	6,857 $200,000
Q2 2022 Aug 11, 2022	BUY	$17.06 - $31.42 $39,800 - $73,302	2,333 Added 17.82%	15,424 $341,000
Q1 2022 May 16, 2022	BUY	$26.68 - $34.81 $349,267 - $455,697	13,091 New	13,091 $386,000
Q3 2021 Nov 12, 2021	SELL	$41.92 - $58.18 $157,535 - $218,640	-3,758 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$52.06 - $61.27 $26,706 - $31,431	-513 Reduced 12.01%	3,758 $207,000
Q1 2021 May 14, 2021	SELL	$44.23 - $57.5 $74,527 - $96,887	-1,685 Reduced 28.29%	4,271 $220,000
Q4 2020 Feb 12, 2021	SELL	$33.21 - $46.54 $14,014 - $19,639	-422 Reduced 6.62%	5,956 $258,000
Q3 2020 Nov 12, 2020	BUY	$33.87 - $55.93 $33,632 - $55,538	993 Added 18.44%	6,378 $225,000
Q2 2020 Aug 14, 2020	BUY	$34.45 - $53.48 $185,513 - $287,989	5,385 New	5,385 $288,000
Q1 2020 May 15, 2020	SELL	$31.52 - $53.81 $237,282 - $405,081	-7,528 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$30.08 - $50.59 $13,746 - $23,119	457 Added 6.46%	7,528 $363,000
Q3 2019 Nov 14, 2019	BUY	$32.4 - $49.58 $229,100 - $350,580	7,071 New	7,071 $229,000

Others Institutions Holding AGIO

# of Institutions

226

Shares Held

56.3M

Call Options Held

275K

Put Options Held

251K

View Full List

About AGIOS PHARMACEUTICALS, INC.

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $2.63B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

More about AGIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Agios Pharmaceuticals, Inc. Transaction History